The Children’s Cancer Institute at the Joseph M. Sanzari Children’s Hospital has officially launched a new study for children with aggressive brain tumors. The 2-hydroxoleic acid study will advance much-needed research in the area of pediatric brain cancer.
In conjunction with the pharmaceutical company Laminar Pharma, and with the support of the Matthew Larson Foundation and the Kortney Rose Foundation, the 2-hydroxoleic study is open and will allow for up to 28 enrollees. The trial is geared toward children with high-grade glioma, DIPG, and other relapsed brain tumors who have few or no good alternative treatments.
This is a trailblazing study, as it is the first time this drug will be used in the United States and tested on children. The drug can be taken orally and is expected to have few side effects, making it a potential good option for young patients.
The 2-hydroxoleic study is the latest development in the Children’s Cancer Institute’s work to advance pediatric neuro-oncology research. The Pediatric Neuro-Oncology Lab, led by neuro-oncologist Dr. Derek Hanson and surgeon-scientist Dr. Timothy Vogel, recently opened at the Center for Discovery and Innovation (CDI), and it will also continue to expand research on rare, aggressive brain tumors.
Support from Tackle Kids Cancer funds and our dedicated partners helps us provide groundbreaking treatment options and research initiatives like this study to benefit patients at the Children’s Cancer Institute.